The pharmaceutical landscape for diabetes is evolving, and transdermal GLP-1 delivery systems represent a potential development. Unlike injections, this technique offers a less invasive way to deliver GLP-1 medications. These transdermal systems slowly release the drug through the surface offering a even amount of the active agent, which can optimi